• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 13

Quantitative syntheses of HDL-c data, for ezetimibe plus statin combination therapy compared with statin monotherapy

Number of trials reporting outcomeNumber of participants in relevant treatment groupsPoint estimateLower CIUpper CI
Difference in mean HDL-c percentage change from baseline (%)
All trials42,46–48,109,110,112,114–118,121,124,126,127,129,130,139,140,142,144,154,156,158,159,166–169,193,1943218143---
Simvastatin
Lower dose statin in combination therapy versus higher dose monotherapy – all participants48,121,130,154,169515850.31−0.891.52
Atorvastatin
Lower dose statin in combination therapy versus higher dose monotherapy – moderately high risk15811842.401.972.83
Participants requiring intensive lipid lowering therapy42,47,112,114–116,118,121,140,142,144,159,167,193,1941570201.530.812.24
Simvastatin
Lower dose statin in combination therapy versus higher dose monotherapy
Participants requiring intensive lipid lowering therapy (diabetes mellitus)121
1210−0.10−3.423.22
Participants with LDL-c>190 mg/dL4217202.40−0.235.03
Participants with diabetes mellitus118,121,144,167,193,19462790---
Participants with vascular disease114,116,14039240.04−1.631.72
All participants of African origin11712673.300.356.25
All participants of Hispanic origin11711470.30−3.644.24

Abbreviations: CI = 95% confidence interval, HDL-c = high density lipoprotein cholesterol, LDL-c = low density lipoprotein cholesterol

From: 3, Results

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.